Recent advances in developing small-molecule inhibitors against SARS-CoV-2.
Acta Pharm Sin B
; 12(4): 1591-1623, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-1293568
ABSTRACT
The COVID-19 pandemic caused by the novel SARS-CoV-2 virus has caused havoc across the entire world. Even though several COVID-19 vaccines are currently in distribution worldwide, with others in the pipeline, treatment modalities lag behind. Accordingly, researchers have been working hard to understand the nature of the virus, its mutant strains, and the pathogenesis of the disease in order to uncover possible drug targets and effective therapeutic agents. As the research continues, we now know the genome structure, epidemiological and clinical features, and pathogenic mechanism of SARS-CoV-2. Here, we summarized the potential therapeutic targets involved in the life cycle of the virus. On the basis of these targets, small-molecule prophylactic and therapeutic agents have been or are being developed for prevention and treatment of SARS-CoV-2 infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
Acta Pharm Sin B
Year:
2022
Document Type:
Article
Affiliation country:
J.apsb.2021.06.016
Similar
MEDLINE
...
LILACS
LIS